JERUSALEM - Entera Bio Ltd . (NASDAQ: NASDAQ:ENTX), a biotechnology firm specializing in orally delivered peptides, has disclosed positive pharmacokinetic outcomes from a study conducted in collaboration with OPKO Health, Inc. (NASDAQ: OPK). The research focused on a first-of-its-kind oral tablet form of a GLP-2 agonist for patients with short bowel syndrome (SBS) and related conditions.
The current standard treatment for SBS involves daily injections of a GLP-2 agonist, marketed as Gattex® (teduglutide). Entera Bio's oral tablet, developed using their proprietary N-Tab™ technology, aims to offer a more convenient alternative. The proof of concept study in rodents compared the oral tablets with intravenous (IV) injections and found that the oral form resulted in plasma levels approximately ten times higher than those achieved by the injected teduglutide.
According to Entera CEO Miranda Toledano, the study's findings support the potential of the oral GLP-2 tablet to improve treatment compliance and effectiveness for SBS patients. The company plans to proceed with further in vivo pharmacologic assessments and expects to provide updates later in 2024.
SBS is a serious condition where patients cannot adequately absorb nutrients due to the loss of functional bowel mass. It is a leading cause of chronic intestinal failure in adults and children. Entera Bio's work in this field is part of a broader effort to develop oral peptide therapies for various medical needs.
Entera Bio's product pipeline includes several oral peptide programs, with their most advanced candidate, EB613, designed as an oral treatment for post-menopausal osteoporosis. They are also working on the first oral tablet form of oxyntomodulin for obesity treatment and the oral GLP-2 peptide tablet in partnership with OPKO Health.
This news is based on a press release statement from Entera Bio Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.